Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 30;25(1):543.
doi: 10.3390/ijms25010543.

Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review

Matthew J Hadfield  1 , Kathryn DeCarli  1 , Kinan Bash  2 , Grace Sun  1 , Khaldoun Almhanna  1
Affiliations
Review

Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review

Matthew J Hadfield et al. Int J Mol Sci. .

Abstract

Cholangiocarcinoma is a malignancy of the bile ducts that is often associated with late diagnosis, poor overall survival, and limited treatment options. The standard of care therapy for cholangiocarcinoma has been cytotoxic chemotherapy with modest improvements in overall survival with the addition of immune checkpoint inhibitors. The discovery of actionable mutations has led to the advent of targeted therapies against FGFR and IDH-1, which has expanded the treatment landscape for this patient population. Significant efforts have been made in the pre-clinical space to explore novel immunotherapeutic approaches, as well as antibody-drug conjugates. This review provides an overview of the current landscape of treatment options, as well as promising future therapeutic targets.

Keywords: biomarker; cholangiocarcinoma; gallbladder cancer; hepatobiliary malignancy; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of current therapeutic targets in cholangiocarcinoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 2023;73:17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Valle J.W., Lamarca A., Goyal L., Barriuso J., Zhu A.X. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017;7:943–962. doi: 10.1158/2159-8290.CD-17-0245. - DOI - PMC - PubMed
    1. Duffy A., Capanu M., Abou-Alfa G., Huitzil D., Jarnagin W., Fong Y., D’Angelica M., DeMatteo R., Blumgart L., O’Reilly E. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC) J. Surg. Oncol. 2008;98:485–489. doi: 10.1002/jso.21141. - DOI - PubMed
    1. Nagino M., Ebata T., Yokoyama Y., Igami T., Sugawara G., Takahashi Y., Nimura Y. Evolution of surgical treatment for perihilar cholangiocarcinoma: A single-center 34-year review of 574 consecutive resections. Ann. Surg. 2013;258:129–140. doi: 10.1097/SLA.0b013e3182708b57. - DOI - PubMed
    1. Primrose J.N., Fox R.P., Palmer D.H., Malik H.Z., Prasad R., Mirza D., Anthony A., Corrie P., Falk S., Finch-Jones M., et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–673. doi: 10.1016/S1470-2045(18)30915-X. - DOI - PubMed

Substances